Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Latest from Vanderbilt-Ingram Cancer Center


Lurbinectedin Makes a Splash in Second-Line SCLC

April 05, 2021

Wade T. Iams, MD, discusses the efficacy and safety of lurbinectedin in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.

x